• Explore /
  • Poster
  • / Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.

Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.

Abstract Poster

Authors

Yelena Janjigian

Yelena Y. Janjigian

Memorial Sloan Kettering Cancer Center, New York, NY

Yelena Y. Janjigian , Do-Youn Oh , Sun Young Rha , Keun Wook Lee , Neeltje Steeghs , Yee Chao , Maria Di Bartolomeo , Marc Díez Garcia , Nadia Haj Mohammad , Alexander Stein , William McAdoo , Megan Winter , Liz Croydon , Jeeyun Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04379596

DOI

10.1200/JCO.2022.40.4_suppl.295

Abstract #

295

Poster Bd #

L4

Abstract Disclosures

Similar Posters

First Author: Yelena Y. Janjigian

First Author: Yelena Y. Janjigian

First Author: Zhi Peng

First Author: Kohei Shitara